See more from Benzinga
Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations
AIM ImmunoTech Recruits hVIVO For Ampligen Trial For Prophylaxis Use Against Respiratory Viruses
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
"We are not very ambitious. I should be careful about talking about work-life balance, but the Americans just work harder.”
In his 2016 letter to Berkshire Hathaway shareholders, legendary investor Warren Buffett wrote, “Every decade or so, dark clouds will fill the economic skies, and they will briefly rain gold. When downpours of that sort occur, it’s imperative that we ...
The March reading comes as investors have continued to scale back their expectations on when the Federal Reserve will cut interest rates in 2024, if at all.
It's possible to construct a winning long-term investment strategy with just low-cost index funds.
As US growth shows signs of sputtering and inflation keeps rising, a re-run of the tumultuous 1970s is looking more likely.
The combination of artificial intelligence (AI) and cybersecurity is a match made in heaven.
Rooting for Donald Trump to fail has rarely been this profitable. Just ask a hardy band of mostly amateur Wall Street investors who have collectively made tens of millions of dollars over the past month by betting that the stock price of his social media business — Truth Social — will keep dropping despite massive buying by Trump loyalists and wild swings that often mirror the candidate’s latest polls, court trials and outbursts on Trump Social itself.
(Reuters) -AbbVie raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug Imbruvica helped the company beat Wall Street estimates for the first quarter. Shares of AbbVie rose nearly 2.5% in premarket trading. The company now expects adjusted profit of between $11.13 and $11.33 per share for this year, compared with $10.97 to $11.17 estimated earlier.
As U.S. inflation worries grow, some investors are preparing for the 10-year U.S. Treasury yield to breach a 16-year high of 5% hit last October. Bond yields, which move inversely to prices, have climbed in recent weeks as signs of persistent inflation erode expectations for how deeply the Federal Reserve will be able to cut interest rates without further fueling consumer prices. Many investors are betting further weakness lies ahead for bonds.
This company should continue to make millionaires, just as it has over the past two decades.